Skip to Main content Skip to Navigation
Journal articles

Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC)

Cindy Neuzillet 1 Sebastien Gaujoux 2, 3 Nicolas Williet 4 Jean-Baptiste Bachet 5 Lucile Bauguion Laurianne Colson Durand Thierry Conroy 6 Laetitia Dahan 7 Marine Gilabert 8 Florence Huguet 9 Lysiane Marthey 10 Julie Meilleroux 11 Louis Mestier Bertrand Napoleon 12 Fabienne Portales 13 Antonio Sa Cunha 14 Lilian Schwarz 15, 16 Julien Taieb 17 Benoist Chibaudel 18 Olivier Bouche 19 Pascal Hammel 20 Thesaurus Natl Cancerologie Dig Soc Natl Francaise Gastroenterol Federation Francophone Cancerolo Grp Cooperateur Multidisciplinair Federation Natl Ctr Lutte Contre Soc Francaise Chirurg Digestive Soc Francaise Diges Soc Francaise Radiotherapie Oncolo Assoc Chirurg Hepato-Bilio-Pancrea Assoc Francaise Chirurg Afc
Abstract : Background: This document is a summary of the French intergroup guidelines regarding the management of pancreatic adenocarcinoma (PA), updated in July 2018. Design: This collaborative work was produced under the auspices of all French medical and surgical societies involved in the management of PA. It is based on the previous guidelines, recent literature review and expert opinions. Recommendations were graded in three categories, according to the level of evidence. Results: Over the last seven years, significant changes in PA management have been implemented in clinical practice. Imaging/staging: diffusion magnetic resonance imaging is useful before surgery to rule out small liver metastases. Surgery: centralization of pancreatic surgery in expert centers is associated with a decreased postoperative mortality. Adjuvant chemotherapy: modified FOLFIRINOX in fit patients, or gemcitabine, or 5-FU, or gemcitabine plus capecitabine, to be discussed on a case-by-case basis. Locally advanced PA: no survival benefit of chemoradiotherapy. Metastatic PA: FOLFIRINOX and gemcitabine plus nab-paclitaxel combination are first-line standards in fit patients; second-line with 5FU/nal-IRI or 5FU/oxaliplatin combination after first-line gemcitabine. Conclusion: Guidelines for management of PA are continuously evolving and need to be regularly updated. This constant progress is made possible through clinical and translational research. However, as each individual case is particular, they cannot substitute to multidisciplinary tumor board discussion. (C) 2018 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
Document type :
Journal articles
Complete list of metadatas

https://hal-amu.archives-ouvertes.fr/hal-02143547
Contributor : Ghislain Bidaut <>
Submitted on : Wednesday, May 29, 2019 - 2:47:04 PM
Last modification on : Wednesday, October 14, 2020 - 3:50:31 AM

Identifiers

Citation

Cindy Neuzillet, Sebastien Gaujoux, Nicolas Williet, Jean-Baptiste Bachet, Lucile Bauguion, et al.. Pancreatic cancer: French clinical practice guidelines for diagnosis, treatment and follow-up (SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, AFC). DIGESTIVE AND LIVER DISEASE, 2018, 50 (12), pp.1257-1271. ⟨10.1016/j.dld.2018.08.008⟩. ⟨hal-02143547⟩

Share

Metrics

Record views

366